2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-123846
    MLS-0437605 862975-18-6 99.27%
    MLS-0437605 is a selective dual-specificity phosphatase 3 (DUSP3) inhibitor with an IC50 of 3.7 μM. MLS-0437605 is more selective for DUSP3 than DUSP22 and other protein tyrosine phosphatases (PTPs).
    MLS-0437605
  • HY-124750
    NecroX-7 1120332-55-9 99.69%
    NecroX-7 is a potent free radical scavenger and a HMGB1 (high-mobility group box 1) inhibitor. NecroX-7 can be used as an antidote to acetaminophen toxicity. NecroX-7 exerts a protective effect by preventing the release of HMGB1 in ischemia/reperfusion injury. NecroX-7 inhibits the HMGB1-induced release of TNF and IL-6, as well as the expression of TLR-4 and receptor for advanced glycation end products. NecroX-7 can be used graft-versus-host disease (GVHD) research.
    NecroX-7
  • HY-145793
    FTT5 2328129-27-5 ≥98.0%
    FTT5 is an ionizable lipid that can be used to prepare lipid nanoparticles for efficient delivery of long-chain mRNA in vivo.
    FTT5
  • HY-150123
    Quinidine methiodide 42982-87-6
    Quinidine methiodide is a metabolite of Quinidine. Quinidine is an antiarrhythmic agent.
    Quinidine methiodide
  • HY-150793
    SY-LB-57 2253719-35-4 99.66%
    SY-LB-57 is a highly potent bone morphogenetic protein (BMP) receptor signaling agonist. SY-LB-57 can be used in studies of diseases such as fractures and pulmonary arterial hypertension.
    SY-LB-57
  • HY-P1196A
    Kisspeptin 234 TFA 1848962-29-7 98.92%
    Kisspeptin 234 TFA, is a 10 amino acid peptide as well as a kisspeptin receptor (KISS1, GPR54) antagonist. Kisspeptin 234 TFA is an analog of Kisspeptin 10.
    Kisspeptin 234 TFA
  • HY-Y0682B
    Ethylenediaminetetraacetic acid tetrasodium 64-02-8 ≥98.0%
    Ethylenediaminetetraacetic acid (EDTA) tetrasodium is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid tetrasodium has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid tetrasodium decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid tetrasodium can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid tetrasodium can be used for coronary artery disease and neural system disease research.
    Ethylenediaminetetraacetic acid tetrasodium
  • HY-106262B
    Delcasertib hydrochloride 99.73%
    Delcasertib (KAI-9803) hydrochloride is a potent and selective δ-protein kinase C (δPKC) inhibitor. Delcasertib (KAI-9803) hydrochloride could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI).
    Delcasertib hydrochloride
  • HY-122560A
    VU0134992 hydrochloride 1052515-91-9 98.34%
    VU0134992 hydrochloride is the first subtype-preferring, orally active and selective Kir4.1 potassium channel pore blocker, with an IC50 of 0.97 µM. VU0134992 hydrochloride is 9-fold selective for homomeric Kir4.1 over Kir4.1/5.1 concatemeric channels (IC50=9 µM) at -120 mV.
    VU0134992 hydrochloride
  • HY-W017007
    3-Methyl-L-histidine 368-16-1 99.98%
    3-Methyl-L-histidine is an endogenous amino acid that can be found in actin and myosin.
    3-Methyl-L-histidine
  • HY-P0019
    Z-Gly-Gly-Arg-AMC 66216-78-2 99.90%
    Z-Gly-Gly-Arg-AMC is a thrombin-specific fluorogenic substrate for testing of thrombin generation in PRP and platelet-poor plasma (PPP) (Ex/Em = 390/480 nm).
    Z-Gly-Gly-Arg-AMC
  • HY-113469
    Cyclic GMP 7665-99-8 99.43%
    Cyclic GMP (cGAMP) is an endogenous second messenger that triggers interferon production in response to cytoplasmic DNA. Cyclic GMP can activate the stimulator of interferon genes (STING), activating the signaling cascade that leads to the production of type I interferons and other immune mediators. Cyclic-GMP-AMP, a conjugate of cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses. cGMP may also activate PDE to degrade cAMP, inhibit myocardial calcium current ICa, and regulate myocardial contractility. The derivative of cyclic GMP (cGMP), 8-Br-cGMP, has antiplatelet activity, and cyclic GMP can be used in the study of antiviral immunity and cardiovascular diseases.
    Cyclic GMP
  • HY-14255
    Levcromakalim 94535-50-9 99.83%
    Levcromakalim ((-)-Cromakalim) is an ATP-sensitive K+ channel (KATP) activator.
    Levcromakalim
  • HY-19749
    PD 151746 181765-30-0
    PD151746 is a calpain inhibitor, shows a 20-fold selectivity for u-calpain (Ki = 0.
    PD 151746
  • HY-114349
    HS-1371 2158197-70-5 99.89%
    HS-1371 is a potent and ATP-competitive receptor-interacting protein kinase 3 (RIP3) inhibitor with an IC50 of 20.8 nM.
    HS-1371
  • HY-124756
    SBI-425 1451272-71-1 98.88%
    SBI-425 is an orally active and potent TNAP (tissue-nonspecific alkaline phosphatase) inhibitor (IC50=16 nM). SBI-425 inhibits TNAP in the vasculature, improving cardiovascular parameters and survival.
    SBI-425
  • HY-17352
    Clazosentan 180384-56-9 99.50%
    Clazosentan (Ro 61-1790) is a selective endothelin A (ETA) receptor antagonist. Clazosentan inhibits ET-1-mediated vasoconstriction. Clazosentan prevents cerebral vasospasm, vasospasm-related cerebral infarction.
    Clazosentan
  • HY-B0341
    Nicorandil 65141-46-0 98.20%
    Nicorandil (SG-75) is a potent potassium channel activator and targets vascular nucleoside diphosphate-dependent K+ channels and cardiac ATP-sensitive K+ channels (KATP). Nicorandil is a nicotinamide ester with vasodilatory and cardioprotective effects and has the potential for angina and forischemic heart diseases.
    Nicorandil
  • HY-B0584
    Travoprost 157283-68-6 99.99%
    Travoprost (Fluprostenol isopropyl ester), an isopropyl ester proagent, is a high affinity, selective FP prostaglandin full receptor agonist. Travoprost has the ocular hypotensive efficacy and has the potential for glaucoma and ocular hypertension.
    Travoprost
  • HY-P99491
    Camoteskimab 2492472-82-7 ≥99.0%
    Camoteskimab (AVTX-007) is an anti-IL-18 monoclonal antibody with fully humanized, high-affinity. Camoteskimab specifically binds IL-18 and blocks the interaction of IL-18 with its receptor. Camoteskimab is promising for research of cardiovascular diseases and autoinflammatory diseases, including adult-onset Still’s disease (AOSD) and multiple myeloma.
    Camoteskimab
Cat. No. Product Name / Synonyms Application Reactivity